Summary — HB 1703 (as provided)
Note on sources and status
- The documents you supplied mix material from multiple states (primarily Arkansas, but also snippets from Indiana and Illinois) and contain inconsistent legislative-action metadata (some entries show passage and enrollment while the bill status you supplied says “Died In Committee”).
- The text below summarizes the substantive bill language contained in the provided Arkansas draft (95th General Assembly, Regular Session 2025, Engrossed H3/18/25, Sponsor: Rep. L. Johnson). Before relying on this for legal or compliance purposes, verify the bill’s final text and official status in the relevant state’s legislative records.
Purpose and intent
- Create a statutory drug-reimbursement appeal process requiring healthcare insurers and health benefit plans (and their contracting entities) to provide an administrative procedure by which a healthcare provider can challenge a drug reimbursement that is below the provider’s drug acquisition cost. The goal is to ensure providers receive reimbursement at or above a defined floor when acquisition costs exceed contracted rates.
Key provisions
- New subchapter added to Arkansas Code Title 23, Chapter 99 (Subchapter 19 — Drug Reimbursement Process; sections 23-99-1901 and 23-99-1902).
- Definitions: clarifies “contracting entity,” “drug” (including prescription drugs, biologics, radiopharmaceuticals, etc.), “health benefit plan,” “healthcare insurer,” “healthcare provider,” and “healthcare services.” (Notably excludes services reimbursed through PBMs licensed under the Arkansas PBM Licensure Act.)
- Appeal mechanism:
- Contracting entities must provide a reasonable administrative appeal procedure, including direct submission to the insurer/plan, and dedicated phone/email/website contacts.
- Providers may file an administrative appeal no later than 60 business days after claim adjudication.
- Timing and outcomes:
- Contracting entity must act within 30 business days of receipt of the appeal.
- If the appeal is upheld, the reimbursement rate must be adjusted to at least 110% of the provider’s drug acquisition cost.
- The claim must be reprocessed at that rate, and subsequent claims for the same drug (identified by NDC or HCPCS) must be processed at that rate.
- If denied, the contracting entity must provide specific reasons and any additional information necessary to establish acquisition cost.
- Duration of adjusted rate:
- If the appeal is initiated before the last month of the contracting entity’s fiscal quarter, the adjusted rate remains through the end of that fiscal quarter.
- If initiated during the last month of the fiscal quarter, the rate remains through the end of the following fiscal quarter.
- Quarterly notice option:
- Providers may submit quarterly notices listing drugs whose acquisition cost is below contracted reimbursement.
- On receipt, the contracting entity may voluntarily change reimbursement to at least 110% of acquisition cost without an appeal.
Who would be affected
- Directly affected:
- Healthcare providers (physicians, clinics, hospitals, infusion centers, other licensed providers) that purchase and administer drugs and may incur acquisition costs higher than insurer-contracted reimbursement.
- Contracting entities and healthcare insurers/health benefit plans operating in the state, which would need to implement the appeal processes and may face increased drug-related payouts.
- Not covered:
- Services reimbursed through pharmacy benefit managers (PBMs) licensed under the Arkansas PBM Licensure Act are excluded from the “healthcare services” definition in this subchapter.
- Certain types of benefit plans (e.g., dental-only, vision-only, workers’ compensation, etc.) are excluded from the “health benefit plan” definition.
Procedural/timing highlights in the text
- Appeal filing window: within 60 business days after claim adjudication.
- Contracting entity response: within 30 business days.
- Adjusted reimbursement lasting through a fiscal quarter or the following quarter depending on timing.
- Quarterly notice mechanism allowing proactive rate adjustments without formal appeals.
Potential impacts (practical considerations)
- Providers: could recover additional payment when acquisition cost exceeds contracted rates; administrative avenue to document acquisition costs.
- Insurers/plans: increased administrative duties (set up appeal portals, dedicated contacts) and potential increased drug expenditures when rates are adjusted to 110% of acquisition cost.
- Market/pricing: may shift negotiation dynamics between providers, insurers, and PBMs; potential downstream effects on premiums or plan costs.
- Limited scope: the statute’s exclusions (PBM-managed pharmacy services, certain plan types) constrain applicability.
Related/ancillary notes
- Amendment H1 in the provided materials clarifies the same timing and quarterly-notice provisions described above.
- The materials mention companion bills (SB 233, HB 1157) and multiple sponsors (Rep. L. Johnson; Sen. Irvin), but the supplied materials also include unrelated sponsors (e.g., Rep. Fred Crespo) and text from other states—confirm sponsorship and cross-filed bills in the official state docket.
Recommendation
- Verify the bill number, final enacted text (if any), and official status with the Arkansas General Assembly website or the state’s legislative information system because the provided packet contains inconsistent and multi-jurisdictional material.
